PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Cambridge Healthtech Institute

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

CHII Presents the Inaugural Mitigating Safety Risks in Early Clinical Development Executive Forum - Presentations discuss bridging the gap between pre-clinical and clinical safety to improve prediction
CHII Presents the Inaugural Mitigating Safety Risks in Early Clinical Development Executive Forum

 

NewswireToday - /newswire/ - Needham, MA, United States, 2010/08/18 - Presentations discuss bridging the gap between pre-clinical and clinical safety to improve prediction.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Cambridge Healthtech Institute’s BioPharma Strategy Series announces its inaugural Mitigating Safety Risks in Early Clinical Development executive forum to be held November 8-9, 2010 at the Crowne Plaza Philadelphia Downtown in Philadelphia, PA.

The program will focus on clinical risk assessment and bridging the gap between preclinical data and clinical studies and offer strategies to better assess, predict and mitigate safety risks. Preclinical safety and clinical safety participants and presenters will share challenges with their counterparts on the ‘other side’ in order to educate each other and better understand safety in a context that goes beyond one’s immediate purview.

“The program was created as a result of direct requests by leaders in drug safety and risk management, who felt that too much of today’s safety organization is siloed,” said Micah Lieberman, Executive Director of Conferences. “Though most of the discussions are focused on early clinical development and safety, we have shared sessions and breakout discussion groups with our annual Post-Approval Drug Safety audience.”

Leading the way in developing the program agenda are the featured presenters, including James Milligan of AstraZeneca; Arie Regev of Eli Lilly & Company; Phil Sager of Gilead; Stephen Furlong of AstraZeneca; Sandeep Modi of Unilever and Paul Watkins of University of North Carolina, Chapel Hill.

The main conference begins in a shared session in the Post-Approval Drug Safety conference where delegates will hear a three part, co-presentation on “Integrating Drug Safety Knowledge Across a Compound’s Lifecycle and Across a Portfolio.” The themes discussed in the co-presentation include corporate risk management by Michael Forstner M.Sc., Ph.D., Integrated Safety Risk Manager, F. Hoffmann-La Roche, Basel, Switzerland; data mining by Colette F. Saccomanno, Ph.D., MSLIS, Integrated Safety Risk Manager, F. Hoffmann-La Roche; and comparative risk benefit assessment by James Cross, MS, Ph.D., Integrated Safety Risk Manager, Genentech, San Francisco, CA

The rest of the forum features sessions and breakout discussions on Improving Early Assessment, Better Linking Preclinical Data , Clinical Studies and Post-Approval Safety, and New Technologies and Methods. The forum concludes with an interactive panel, entitled “What Predictive Safety Technologies are Being Utilized Upstream and How They May Impact Clinical and Post Approval Safety,” to be hosted by Ernie Bush, Ph.D., Vice President, Collaborative Projects, Drug Safety Executive Council (DSEC).

Advance registration discounts for both drug safety forums are available until September 17, 2010. For complete event details, visit healthtech.com/PTX

To apply for a press pass, please email Tracey Fielding, tfielding[.]healthtech.com.
To inquire about partnering or sponsoring, please contact Arnold Wolfson, awolfson[.]healthtech.com

About Cambridge Healthtech Institute (CHI)
Cambridge Healthtech Institute (healthtech.com) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute (chicorporate.com) strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Cambridge Healthtech Institute

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


CHII Presents the Inaugural Mitigating Safety Risks in Early Clinical Development Executive Forum

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: James Prudhomme - HealthTech.com 
781-972-5400 jprudhomme[.]healthtech.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Cambridge Healthtech Institute securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Cambridge Healthtech Institute / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)